Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Edessa

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Edessa head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 169 · Grade C

Edessa

Visit Edessa Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 70 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make Edessa a bad call — it's best for readers who can obtain a dose-specific quote and the full conditions behind the advertised money-back promise. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
64
Supply Reliability
95
72
Transparency
90
66
Access Breadth
93
82
Clinical Oversight
92
72
Track Record
88
66
CoreAge RxBrief Score 94 · 70Edessa

Price, coverage & the tracker

CoreAge RxEdessa
Brief Score94/100 (A)70/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Confirm dose-specific total

From $135 for the first semaglutide month is advertised; continuing dose, supply and full payment need a quote.

Full price details

Compounded semaglutide offered; complete current dose-specific quote unknown; first-month offer from $135; earlier listing: $179/mo month-to-month injectable (compounded)

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Confirm dose-specific total

Advertised $239 monthly; $219/$209 equivalents require three/six months. Full longer-plan payments need confirmation.

Full price details

Compounded tirzepatide offered; complete current commitment and dose-specific quote unknown; $239 monthly option advertised; earlier listing: $239/mo month-to-month (compounded)

CoverageUS only; restrictions by state, confirmed at intakeAdvertises all 50 states plus DC, with medication and service exceptions
Brand-name accessNot confirmedGeneric FDA-approved medication fulfillment advertised; confirm the current named brand, price and eligibility.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

Edessa: Semaglutide advertises from $135; tirzepatide monthly $239 versus longer-plan equivalents. Complete quotes remain unconfirmed; the refund promise is conditional.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.